BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to T24 cell line is 139
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMI1 | 1066 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by Western Blotting and IF staining | NA | 0.52 | 0.1135 | 24337040 |
| BMI1 | 1066 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | SFA and SP assay followed by RT-PCR and Western Blotting | NA | 0.52 | 0.1135 | 22343321 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | SFA and SP assay followed by Western Blotting and IF staining | NA | 0.52 | 1 | 22343321 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 1 | 24012496 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Western Blotting | NA | 0.52 | 1 | 29559853 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Western Blotting | NA | 0.52 | 1 | 31222373 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by Western Blotting | NA | 0.52 | 1 | 25020236 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.52 | 1 | 28895409 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.52 | 1 | 31187490 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | FACs followed by SFA | NA | 0.52 | 1 | 21964864 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | FACs followed by SFA | NA | 0.52 | 1 | 29340052 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | MACs | NA | 0.52 | 1 | 32192892 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | MACs followed by SFA | NA | 0.52 | 1 | 32626701 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by FACs | NA | 0.52 | 1 | 31176734 |
| CXCL5 | 10642 | LTM | Bladder Cancer | Carcinoma | T24 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.0032 | 34407043 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | SFA and SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 22343321 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | RT-PCR | NA | 0.48 | 0.5461 | 26647959 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 30592142 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31187490 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR and SFA | NA | 0.48 | 0.5461 | 25020236 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | SFA and SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 22343321 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29559853 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | RT-PCR | NA | 0.48 | 0.6448 | 26647959 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 30592142 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.6448 | 24337040 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR and SFA | NA | 0.48 | 0.6448 | 25020236 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1739 | 29559853 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | RT-PCR | NA | 0.28 | 0.1739 | 27474203 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by CFA and RT-PCR | NA | 0.28 | 0.1739 | 19589244 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR | NA | 0.28 | 0.1739 | 24337040 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR and SFA | NA | 0.28 | 0.1739 | 25020236 |
| KLF4 | 6348 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0891 | 29559853 |
| KLF4 | 6348 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR and SFA | NA | 0.28 | 0.0891 | 25020236 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.7582 | 29559853 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.7582 | 30592142 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.7582 | 31187490 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.7582 | 32065779 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by FACs | NA | 0.28 | 0.7582 | 31176734 |
| MAGEB2 | 6809 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0021 | 29340052 |
| ABCB1 | 40 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | RT-PCR | NA | 0.2 | 0.0604 | 26647959 |
| ABCB1 | 40 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | RT-PCR | NA | 0.2 | 0.0604 | 27474203 |
| ABCB1 | 40 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 30592142 |
| ABCB1 | 40 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.0604 | 25020236 |
| ABCC1 | 51 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | RT-PCR | NA | 0.2 | 0.0212 | 26647959 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | RT-PCR | NA | 0.2 | 0.684 | 27474203 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.684 | 28895409 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.684 | 30592142 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.684 | 31187490 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | T24 | Cisplatin | ALDEFLUOR assay followed by CFA | NA | 0.2 | 0.684 | 22399585 |
| BHMT | 1047 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32065779 |
| COX7B2 | 24381 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32065779 |
| MAGEB2 | 6809 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 32065779 |
| SLCO1B3 | 10961 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 32065779 |
| SOX2 | 11195 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.5695 | 31187490 |
| SOX2 | 11195 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.5695 | 25020236 |
| XAGE5 | 30930 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32065779 |
| XIST | 12810 | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by qPCR | NA | 0.2 | 0.0021 | 29559853 |
| OV6 | NA | LTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by FACs | NA | 0.12 | 0.0011 | 30397177 |
| ABCA1 | 29 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30592142 |
| APP | 620 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| ASS1 | 758 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| ATP2A2 | 812 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| BAX | 959 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29340052 |
| C3 | 1318 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 30592142 |
| CDH2 | 1759 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 30592142 |
| CKB | 1991 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| CLEC2B | 2053 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| CPS1 | 2323 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 29340052 |
| CXADR | 2559 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| CXCL11 | 10638 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| CYP1B1 | 2597 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 29340052 |
| DAD1 | 2664 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| DDX60 | 25942 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30592142 |
| DHRS3 | 17693 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30592142 |
| EML2 | 18035 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| ETS1 | 3488 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| FBN1 | 3603 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| GAGE1 | 4098 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE1 | 4098 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE12B | 26779 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE13 | 29081 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE2A | 4099 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE2B | 4099 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE2C | 31906 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE2E | 31960 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAGE8 | 4099 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GAL | 4114 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| GTDC1 | 20887 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| H1-2 | 4716 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29340052 |
| H1-3 | 4717 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| H2AC20 | 4738 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| HIRA | 4916 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| HSPA5 | 5238 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0117 | 29340052 |
| IFI44 | 16938 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| IL24 | 11346 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30592142 |
| IL7R | 6024 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30592142 |
| IL8 | 6025 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0159 | 30592142 |
| LMNB1 | 6637 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| LMNB1 | 6637 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| MAGEA3 | 6801 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| MAGEA6 | 6804 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| MAGOH | 6815 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| MLLT10 | 16063 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| MSL1 | 27905 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| NCOA7 | 21081 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| NPTX1 | 7952 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| NTS | 8038 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| OLR1 | 8133 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| PAG1 | 30043 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30592142 |
| PCIF1 | 16200 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| PCSK9 | 20001 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| PI3 | 8947 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 30592142 |
| PIP5K1A | 8994 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| PLAC8 | 19254 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| PTGS2 | 9605 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 29340052 |
| RANBP2 | 9848 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| RDH10 | 19975 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30592142 |
| RGPD1 | 32414 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RGPD2 | 32415 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RGPD3 | 32416 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RGPD4 | 32417 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RGPD5 | 32418 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RGPD6 | 32419 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RPS6 | 10429 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| S100A4 | 10494 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0074 | 29340052 |
| S100P | 10504 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0106 | 29340052 |
| SCD | 10571 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0127 | 30592142 |
| SCRN1 | 22192 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| SETD5 | 25566 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SLC14A1 | 10918 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| SLC27A2 | 10996 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| SLITRK6 | 23503 | HTM | Bladder Cancer | Carcinoma | T24 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30592142 |
| SUCLG2 | 11450 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| TAOK1 | 29259 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| TNKS2 | 15677 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| WDR3 | 12755 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| WLS | 30238 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| WSB1 | 19221 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| YAP1 | 16262 | HTM | Bladder Cancer | Carcinoma | T24 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0117 | 29340052 |